{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:28:36Z","timestamp":1794536916761,"version":"4.9.1"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The benefit of neoadjuvant camrelizumab plus chemotherapy for resectable stage IIIA or IIIB non\u2013small cell lung cancer (NSCLC) remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy vs chemotherapy alone for patients with resectable stage IIIA or IIIB NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>In this randomized phase 2 clinical trial conducted at 2 hospitals in China, patients aged 18 to 70 years with resectable stage IIIA or IIIB (T3N2) NSCLC were enrolled between April 7, 2020, and January 12, 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>\n                      Patients were randomly assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , and platinum [cisplatin, 75 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; carboplatin, area under the curve, 5; or nedaplatin, 100 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ]) or chemotherapy alone, followed by surgery after 4 to 6 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point was the pathologic complete response (pCR) rate. Secondary end points included the major pathologic response (MPR) rate, objective response rate (ORR), event-free survival (EFS), and safety. Disease-free survival (DFS, defined as the time from surgery to disease recurrence or death from any cause) was analyzed post hoc. Efficacy was assessed on a modified intention-to-treat basis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety-four Chinese patients were randomized, and 88 (93.6%; median age, 61 years [IQR, 54-65 years]; 74 men [84.1%]) received allocated neoadjuvant treatment (43 received camrelizumab plus chemotherapy, and 45 received chemotherapy alone). Among these 88 patients, the pCR rate was 32.6% (14 of 43; 95% CI, 19.1%-48.5%) with camrelizumab plus chemotherapy vs 8.9% (4 of 45; 95% CI, 2.5%-21.2%) with chemotherapy alone (odds ratio, 4.95; 95% CI, 1.35-22.37;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.008). The MPR rates were 65.1% (95% CI, 49.1%-79.0%) with camrelizumab plus chemotherapy and 15.6% (95% CI, 6.5%-29.5%) with chemotherapy alone. The radiographic ORRs were 72.1% (95% CI, 56.3%-84.7%) with camrelizumab plus chemotherapy and 53.3% (95% CI, 37.9%-68.3%) with chemotherapy alone. With a median follow-up of 14.1 months (IQR, 9.2-20.9 months), the median EFS and DFS were not reached in either group. The most common neoadjuvant treatment-related adverse events of grade 3 or higher were decreased white blood cell count (6 of 43 [14.0%] in the camrelizumab plus chemotherapy group vs 2 of 45 [4.4%] in the chemotherapy group) and decreased neutrophil count (3 of 43 [7.0%] in the camrelizumab plus chemotherapy group vs 5 of 45 [11.1%] in the chemotherapy group). No treatment-related deaths were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This randomized clinical trial found that among patients with resectable stage IIIA or IIIB (T3N2) NSCLC, camrelizumab plus chemotherapy, compared with chemotherapy alone, significantly improved the pCR rate with manageable toxic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04338620\">NCT04338620<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.2751","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T11:32:35Z","timestamp":1691062355000},"page":"1348","source":"Crossref","is-referenced-by-count":112,"title":["Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Jie","family":"Lei","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ende","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daixing","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shaanxi Provincial Cancer Hospital, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Lanzhou University, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology Business, Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shaanxi Provincial Cancer Hospital, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"coi230034r1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","article-title":"Immunotherapy in unresectable stage III non\u2013small-cell lung cancer: state of the art and novel therapeutic approaches.","volume":"33","author":"Cortiula","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"coi230034r2","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage iii non\u2013small-cell lung cancer: ASCO guideline.","volume":"40","author":"Daly","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9928","key":"coi230034r3","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non\u2013small-cell lung cancer: a systematic review and meta-analysis of individual participant data.","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"coi230034r4","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1016\/S1470-2045(21)00383-1","article-title":"Revisiting neoadjuvant therapy in non\u2013small-cell lung cancer.","volume":"22","author":"Saw","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"coi230034r5","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease.","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"issue":"21","key":"coi230034r6","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"coi230034r7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non\u2013small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"coi230034r8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial.","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"20","key":"coi230034r9","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"coi230034r10","doi-asserted-by":"publisher","journal-title":"J Thorac Oncol","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"coi230034r11","doi-asserted-by":"publisher","journal-title":"Eur J Cancer","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"16","key":"coi230034r12","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1200\/JCO.2022.40.16_suppl.8501","article-title":"Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: primary end point results of pathological complete response (pCR) from phase II NADIM II trial.","volume":"40","author":"Provencio-Pulla","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi230034r13","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/S1470-2045(17)30691-5","article-title":"Adjuvant chemotherapy with or without bevacizumab in patients with resected non\u2013small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.","volume":"18","author":"Wakelee","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10308","key":"coi230034r14","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non\u2013small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"21","key":"coi230034r15","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi230034r16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/JTO.0b013e3181c814e7","article-title":"Adjuvant cisplatin and vinorelbine for completely resected non\u2013small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.","volume":"5","author":"Douillard","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"9","key":"coi230034r17","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1093\/annonc\/mdt235","article-title":"Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non\u2013small-cell lung cancer.","volume":"24","author":"Socinski","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"coi230034r18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"6","key":"coi230034r19","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non\u2013small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi230034r20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtho.2022.09.222","article-title":"Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II to III NSCLCs: an open-label, multicenter, phase 1b trial.","volume":"18","author":"Yan","year":"2023","journal-title":"J Thorac Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2808073\/jamaoncology_lei_2023_oi_230034_1697125905.97213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T11:10:17Z","timestamp":1697713817000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2808073"}},"subtitle":["The TD-FOREKNOW Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.2751","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}